(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 17.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.59%, and while it is forecast to beat the US market's average forecast revenue growth rate of 16.77%.
Niagen Bioscience's revenue in 2026 is $130,416,000.On average, 7 Wall Street analysts forecast NAGE's revenue for 2026 to be $11,854,261,631, with the lowest NAGE revenue forecast at $11,239,407,426, and the highest NAGE revenue forecast at $12,402,214,600. On average, 6 Wall Street analysts forecast NAGE's revenue for 2027 to be $13,951,296,761, with the lowest NAGE revenue forecast at $12,722,384,795, and the highest NAGE revenue forecast at $14,961,186,827.
In 2028, NAGE is forecast to generate $17,342,552,204 in revenue, with the lowest revenue forecast at $16,403,545,589 and the highest revenue forecast at $18,130,234,598.